Maria Fleseriu, MD
Endocrinology, Diabetes & Metabolism · Portland, ORNPI 1700983574
Payments from drug & device makers
Across 324 payments — averaging $3024.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascendis Pharma Endocrinology Inc$194K
- Novartis$156K
- Novo Nordisk Health Care AG$149K
- Strongbridge US Inc.$122K
- Recordati_rare_diseases_inc.$97K
- Novo Nordisk$76K
- plus $186K from 18 others
Across 9 payments — averaging $2007.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiasma, Inc.$12K
- Pfizer$4K
- Amryt Pharma Holdings Ltd$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 55 | $193,833 |
| Novartis | 20 | $155,765 |
| Novo Nordisk Health Care AG | 45 | $148,975 |
| Strongbridge US Inc. | 31 | $122,091 |
| Recordati_rare_diseases_inc. | 29 | $97,190 |
| Novo Nordisk | 44 | $75,835 |
| Xeris Pharmaceuticals, Inc. | 32 | $52,314 |
| Amryt Pharma Holdings Ltd | 9 | $33,374 |
| Chiasma, Inc. | 5 | $25,594 |
| Novo Nordisk AS | 6 | $15,620 |
| AstraZeneca | 12 | $14,138 |
| Ipsen Innovation | 9 | $11,042 |
| Pfizer | 7 | $5,952 |
| Ipsen Biopharmaceuticals, Inc | 3 | $5,440 |
| Ipsen Biopharm Limited | 2 | $4,625 |
| Ipsen Pharma SAS | 3 | $3,524 |
| HRA Pharma RARE Diseases | 2 | $3,500 |
| Assertio Therapeutics, Inc. | 2 | $2,900 |
| Whitehall International Inc | 1 | $2,800 |
| Pfizer Canada Inc | 3 | $2,036 |
| Chiesi USA, Inc. | 1 | $1,550 |
| H. Lundbeck A S | 1 | $1,200 |
| OPKO Pharmaceuticals, LLC | 1 | $500 |
| Neurocrine Biosciences, Inc. | 1 | $200 |
How this compares
$979,997 in reported general payments places this provider in the 90th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
See all endocrinology, diabetes & metabolism providers in Oregon →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Portland
- Rodica BusuiPortland$2.6M
- Michael McClungPortland$1.3M
- Jonathan PurnellPortland$1.1M
- Andrew AhmannPortland$575K
- Paul DuellPortland$463K
- James NeifingPortland$311K
- Eric OrwollPortland$108K
- Sergio FazioPortland$88K
- Nancy CuroshPortland$59K
- Chaim VanekPortland$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.